Sensible Biotechnologies

What do we do?

Sensible Biotechnologies is a pioneering global biotechnology startup operating in the USA, UK, and Slovakia. Our vision is to bring the next generation of mRNA medicines to patients worldwide. We do this by building the first-in-class cell-based platform to make safer, more effective, and affordable mRNA therapies. In 3 years since its inception, Sensible raised over $10 million from leading specialist life science US and European investors, entered partnerships with leading biotechnology companies, and received designation of Important Project of the Common European Interest by the European Commission. Sensible was featured in the Forbes, Wall Street Journal, Endpoints News, and other global media outlets.

The Sensible Bio Platform
mRNA is typically made via cell-free methods. By leveraging processes in engineered living cells, we produce high-quality mRNA in a cost-efficient and scalable fashion.

• long mRNA opens the path towards novel mRNA-based modalities

• naturally modified mRNA increases the efficacy of mRNA therapies

• cost-effective mRNA manufacturing improves access to mRNA technology

• scalable mRNA production strengthens biosecurity and supply chain resilience

We are combining principles of cell engineering, computational biology and precision cell growth to build the cell-based platform for the manufacturing and design of mRNA vaccines and therapeutics.